GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Wiley  (2)
  • Shen, Bo  (2)
Material
Publisher
  • Wiley  (2)
Language
Years
  • 1
    In: Liver International, Wiley
    Abstract: Liver fibrosis is a wound‐healing reaction that eventually leads to cirrhosis. Hydronidone is a new pyridine derivative with the potential to treat liver fibrosis. In this study, we explored the antifibrotic effects of hydronidone and its potential mode of action. Methods The anti‐hepatic fibrosis effects of hydronidone were studied in carbon tetrachloride (CCl 4 )‐ and 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine (DDC)‐ induced animal liver fibrosis. The antifibrotic mechanisms of hydronidone were investigated in hepatic stellate cells (HSCs). The antifibrotic effect of hydronidone was further tested after Smad7 knockdown in HSCs in mouse models of fibrosis. Results In animal models, hydronidone attenuated liver damage and collagen accumulation, and reduced the expression of fibrosis‐related genes. Hydronidone decreased the expression of fibrotic genes in HSCs. Impressively, hydronidone significantly upregulated Smad7 expression and promoted the degradation of transforming growth factor β receptor I (TGFβRI) in HSCs and thus inhibited the TGFβ‐Smad signalling pathway. Specific knockdown of Smad7 in HSCs in vivo blocked the antifibrotic effect of hydronidone. Conclusion Hydronidone ameliorates liver fibrosis by inhibiting HSCs activation via Smad7‐mediated TGFβRI degradation. Hydronidone is a potential drug candidate for the treatment of liver fibrosis.
    Type of Medium: Online Resource
    ISSN: 1478-3223 , 1478-3231
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2124684-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: The FASEB Journal, Wiley, Vol. 37, No. 5 ( 2023-05)
    Abstract: Liver fibrosis is closely related to the proliferation and differentiation of liver progenitor cells (LPCs). Yes‐associated protein (YAP) is a key effector molecule of the Hippo signaling pathway and plays an important role in regulating cell proliferation and liver homeostasis. However, its role in LPCs proliferation and differentiation during liver fibrosis are not well understood. Using immunohistochemistry, immunofluorescence staining, quantitative PCR and Western blotting, we discovered that LPCs expansion and enhanced YAP expression in LPCs in either choline‐deficient, ethionine‐supplemented (CDE) diet or 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine (DDC) diet‐induced fibrotic mice, as well as in patients with liver fibrosis. By injecting adeno‐associated virus vectors under the transcriptional control of Lgr5 promoter, we found that targeted knockdown of YAP in LPCs attenuated the CDE/DDC diet‐induced ductular reaction and liver fibrosis. Using EdU incorporation and Cell Counting Kit‐8 assays, we demonstrated that YAP can modulate LPCs proliferation. Importantly, spleen transplantation of YAP‐overexpressing LPCs improved their ability to differentiate into hepatocytes and alleviated carbon tetrachloride‐induced liver fibrosis. Collectively, our findings indicate that LPCs expansion and differentiation during liver fibrosis could be modulated by YAP, further suggesting the possibility of manipulating YAP expression in LPCs as a potential treatment for chronic liver diseases.
    Type of Medium: Online Resource
    ISSN: 0892-6638 , 1530-6860
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 1468876-1
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...